Alnylam is sponsoring free, third-party genetic testing and counseling for individuals who may carry a gene mutation known to be associated with hereditary ATTR (hATTR) amyloidosis. The Alnylam Act™ (formerly known as Alnylam Assist) program was created to potentially increase diagnosis rates and to provide genetic counseling to help people make more informed decisions about their health. Learn More.
Results of Survey Assessing Utility and User Experience with Alnylam Act Reported at Annual Clinical Genetics Meeting
We presented results from a survey evaluating the utility and user experience of an independent genetic testing and counseling service for hereditary ATTR (hATTR) amyloidosis that is supported by Alnylam – Alnylam Act – at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting, held March 21 – 25 in Phoenix, Arizona. In May 2016, a 20-question survey was sent to 142 healthcare professionals who registered for an account to use Alnylam Act. The results of the survey demonstrated the free third-party services are useful in diagnosing or ruling out hATTR amyloidosis in individuals at risk based on symptomology or family history. The survey also showed that the program is helping individuals overcome barriers to genetic testing, such as lack of – or inadequate – insurance coverage.
New Exploratory Analysis Results from Fitusiran, an Investigational RNAi Therapeutic for the Treatment of Hemophilia and Rare Bleeding Disorders
We reported new results from an exploratory analysis of our Phase 1 study with fitusiran, an investigational RNAi therapeutic, in patients with hemophilia A or B with or without inhibitors at the 10th Annual Congress of the European Association of Haemophilia and Allied Disorders (EAHAD) held February 1 – 3, 2017 in Paris, France.
On December 16, 2016, we hosted our fourth consecutive R&D Day in New York City. Alnylam management and key opinion leaders discussed our most advanced clinical programs, reviewing all the latest data for patisiran, fitusiran and givosiran.